Wedbush maintains NovoCure at Neutral, lowers price target to $19 from $20

Wedbush kept its Neutral rating on NovoCure but reduced its price target to $19 from $20, a 5% cut. This implies a 51.6% upside from the Nov 9 close of $12.53.

Original reporting
Published Nov 10, 2026, 3:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wedbush maintains NovoCure at Neutral, lowers price target to $19 from $20 — source image
Decision brief

The 30-second read

$NVCRBearishLow
01

Why it matters

The downgrade reflects a modestly more cautious outlook for NovoCure, but without a major catalyst the impact is expected to be limited.

02

Market read

Analyst target adjustments can influence short‑term price movement, especially for small‑cap biotech stocks.

03

What to watch

Potential upcoming clinical data or partnership announcements not covered in the note.

Relevance 5/10Novelty 4/10Timing: today

Background

Wedbush Research provides price target updates as part of its regular coverage of listed companies.

Company-level read

Ticker impact

$NVCRBearishMedium confidence
Context

Wedbush lowered its price target for NovoCure to $19 from $20, indicating a fresh analyst downgrade.

Expected impact

likely modest downside as investors price in the lower target

Evidence & confidence

Target reduction is a new piece of information but limited in scale; no immediate catalyst beyond the rating change.

Market effects

May slightly affect other biotech stocks as analysts adjust expectations.

Limited to US biotech sector.

Low global relevance.

Counterpoint

Some investors may view the target cut as an overreaction and see buying opportunity.

Key entities

  • NovoCure

    Biotech firm developing tumor treating fields therapy.

  • Wedbush

    Equity research firm issuing the target change.

Related articles

$NVCRLowAI 8/10

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

$NVCRMedAI 8/10

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

NovoCure's (NVCR) shares fell 6% after the FDA rejected its Optune Mya device for lung cancer brain metastases, citing uncertainty about clinical benefits. The company plans to meet with FDA officials to discuss a potential approval path. NovoCure's other Optune devices, Gio, Lua, and Pax, are approved and generating revenue, but the company remains unprofitable. The FDA's decision adds to investor concerns about competition from Revolution Medicines' Rasonque pill.

$NVCRHighAI 9/10

Novocure’s device for treating brain metastases rejected by FDA

The FDA rejected Novocure's PMA for Optune Mya, a device for treating brain metastases, citing uncertainty about clinical benefits. The FDA did not raise safety concerns. Novocure plans to discuss feedback with the FDA to explore approval options, but there is no guarantee of future approval. The company has FDA approvals for other TTFields therapies, including Optune Gio, Lua, and Pax.